A robust automated measure of average antibody staining in immunohistochemistry images

Journal of Histochemistry and Cytochemistry

Volumn 58, Issue 2, 2010, Pages 95-107

  Choudhury, Kingshuk Roy ^a   Yagle, Kevin J ^b   Swanson, Paul E ^c   Krohn, Kenneth A ^b   Rajendran, Joseph G ^b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Automated scoring; Cancer markers; IHC

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; VASCULOTROPIN;

ARTICLE; AVERAGED THRESHOLD MEASURE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CONTROLLED STUDY; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; PATHOLOGIST; PRIORITY JOURNAL; SCORING SYSTEM; SIMULATION; SQUAMOUS CELL CARCINOMA; TUMOR BIOPSY; UTERINE CERVIX CARCINOMA; VALIDATION STUDY;

ANTIBODIES; AUTOMATION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; MOLECULAR IMAGING; STAINING AND LABELING; TUMOR MARKERS, BIOLOGICAL;

EID: 76649143080     PISSN: 00221554     EISSN: None     Source Type: Journal    
DOI: 10.1369/jhc.2009.953554     Document Type: Article

References (16)

1. Allred DC (2008) Estrogen and progesterone receptors as predictive markers for breast cancer and DCIS. http://www.asbd.org/ images/D3S9%20- %20Craig%20Allred.pdf (accessed November 9, 2009)
2. Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155-168
3. Altman DG, Lausen B, Sauerbrei W, Schumacher M (1994) Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 86:829-835
4. American Society of Clinical Oncology (1998) Update of recommendations for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 16:793-795
5. Grandis JR (2006) Prognostic biomarkers in head and neck cancer. Clin Cancer Res 12:5005-5006
6. Hanna W (2001) Testing for HER2 status. Oncology 61(suppl 2): 22-30
7. Harvey JM, Clark GM, Osborne K, Allred DC (1999) Estrogen receptor status by IHC is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474-1491
8. Hatanaka Y, Hashizume K, Nitta K, Kato T, Itoh I, Tani Y (2003) Cytometrical image analysis for immunohistochemical hormone receptor status in breast carcinomas. Pathol Int 53:693-699
9. Hsu S-M, Raine L, Fanger H (1981) Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29:577-580
10. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, et al. (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4:844-847
11. Lossos IS, Morgensztern D (2006) Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol 24:995-1007
12. McCluggage WG (2007) Immunohistochemistry as a diagnostic aid in cervical pathology. Pathology 39:97-111
13. Schiffer E (2007) Biomarkers for prostate cancer. World J Urol 25: 557-562
14. Shepp LA, Vardi Y (1982)Maximum likelihood reconstruction in positron emission tomography. IEEE Trans Med Imaging 1:113-122
15. Umemura S, Osamura RY (2004) Utility of immunohistochemistry in breast cancer practice. Breast Cancer 11:334-338
16. Zar J (1998) Biostatistical Analysis. 4th ed. Upper Saddle River, NJ, Prentice Hall